DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Meier-Gorlin syndrome — screening already-approved drugs against its 10-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMeier-Gorlin syndrome maps to a 10-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for meier-gorlin syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
origin recognition complex subunit 4 (ORC4) — ORC4 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet atpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7JPO · 3.2 Å · ligand ADENOSINE-5'-TRIPHOSPHATE (ATP). Experimental structure, not a prediction.
What the evidence adds up to
Meier-Gorlin syndrome is defined by a triad of short stature, small ears, and small or absent kneecaps, with variable expressivity. A 2015 report identified a homozygous deleterious mutation in the ORC6 gene in fetuses at the severe end of the spectrum, including severe intrauterine growth retardation, dislocated knees, gracile bones, clubfeet, and a small mandible and chest. The authors note that previously ORC6-associated Meier-Gorlin syndrome had been considered mild compared to other genetic loci, but this report expands the phenotype to include severely abnormal embryological development, suggesting a possible genotype-phenotype correlation.
A 2014 case report describes a seven-year-old girl with the classical triad plus fenestrated interatrial septal defect, a congenital heart abnormality rarely observed in the syndrome. She had normal mentality but defective speech, skeletal abnormalities, conductive hearing loss, cystitis, and normal growth hormone levels. She suffered recurrent chest infections during the first year of life, which improved gradually with age. No treatment or intervention is discussed in either report.
Earlier work from 2011 identified mutations in the origin recognition complex genes ORC4 and ORC1 as causes of Meier-Gorlin syndrome or a microcephalic primordial dwarfism resembling it. These genetic findings established the link between DNA replication origin licensing and the syndrome, but no therapeutic implications are described.
What remains missing is any clinical trial, any drug tested, any attempt to modify the course of the disease, and any patient stratification beyond genetic diagnosis. No therapy exists; the literature consists entirely of case reports and genetic discovery.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Medical Genetics Part A · 2015 · 14 citations
Further insight into the phenotype associated with a mutation in the <i>ORC6</i> gene, causing Meier–Gorlin syndrome 3
AbstractMutations in genes encoding the origin recognition complex subunits cause Meier-Gorlin syndrome. The disease manifests a triad of short stature, small ears, and small and/or absent patellae with variable expressivity. We report on the identification of a homozygous deleterious mutation in the ORC6 gene in previously described fetuses at the severe end of the Meier-Gorlin spectrum. The phenotype included severe intrauterine growth retardation, dislocation of knees, gracile bones, clubfeet, and small mandible and chest. To date, the clinical presentation of ORC6-associated Meier-Gorlin syndrome has been mild compared to other the phenotype associated with other loci. The present report expands the clinical phenotype associated with ORC6 mutations to include severely abnormal embryological development suggesting a possible genotype-phenotype correlation.
Egyptian Journal of Medical Human Genetics · 2014 · 8 citations · open access
Meier-Gorlin syndrome: Report of an additional patient with congenital heart disease
AbstractWe report a 7 year old female child with the classical triad of Meier-Gorlin syndrome (MGS), (microtia, absent patella and short stature). She had the characteristic facial features, with normal mentality and defective speech, skeletal abnormalities, conductive hearing loss, cystitis and normal growth hormone level. She suffered from recurrent chest infection during the first year of life which improved gradually with age. Although congenital heart is rarely observed in MGS, our patient had in addition fenestrated interatrial septal defect.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
